Myxobacterial natural products: an under-valued source of products for drug discovery for neurological disorders

Mona Dehhaghi, Fatemeh Mohammadipanah*, Gilles J. Guillemin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)


Age-related disorders impose noticeable financial and emotional burdens on society. This impact is becoming more prevalent with the increasing incidence of neurodegenerative diseases and is causing critical concerns for treatment of patients worldwide. Parkinson's disease, Alzheimer's disease, multiple sclerosis and motor neuron disease are the most prevalent and the most expensive to treat neurodegenerative diseases globally. Therefore, exploring effective therapies to overcome these disorders is a necessity. Natural products and their derivatives have increasingly attracted attention in drug discovery programs that have identified microorganisms which produce a large range of metabolites with bioactive properties. Myxobacteria, a group of Gram-negative bacteria with large genome size, produce a wide range of secondary metabolites with significant chemical structures and a variety of biological effects. They are potent natural product producers. In this review paper, we attempt to overview some secondary metabolites synthesized by myxobacteria with neuroprotective activity through known mechanisms including production of polyunsaturated fatty acids, reduction of apoptosis, immunomodulation, stress reduction of endoplasmic reticulum, stabilization of microtubules, enzyme inhibition and serotonin receptor modulation.

Original languageEnglish
Pages (from-to)195-203
Number of pages9
Publication statusPublished - May 2018


  • Drug discovery
  • Myxobacteria
  • Natural products
  • Neurodegenerative diseases

Fingerprint Dive into the research topics of 'Myxobacterial natural products: an under-valued source of products for drug discovery for neurological disorders'. Together they form a unique fingerprint.

Cite this